Royalty Obligation. Subject to Section 4.2, with respect to each Royalty-Bearing Product, Celldex shall pay to Medarex a royalty on annual (based on a calendar year) aggregate worldwide Net Sales of Royalty-Bearing Products on a Royalty-Bearing Product-by-Royalty-Bearing Product basis as follows:
Appears in 2 contracts
Sources: Assignment and License Agreement (Celldex Therapeutics Inc), Assignment and License Agreement (Celldex Therapeutics Inc)
Royalty Obligation. Subject to Section 4.2, with respect to each Royalty-Bearing Product, Celldex shall pay to Medarex a royalty on annual (based on a calendar year) aggregate worldwide Net Sales of Royalty-Bearing Products on a Royalty-Bearing Product-by-Royalty-Bearing Product basis as follows:: Portion of Annual Net Sales í*****] Portion of Annual Net Sales [*****]
Appears in 1 contract
Sources: Assignment and License Agreement (Celldex Therapeutics Inc)
Royalty Obligation. Subject to Section 4.2, with respect to each Royalty-Bearing Product, Celldex shall pay to Medarex a royalty on annual (based on a calendar year) aggregate worldwide Net Sales of Royalty-Bearing Products on a Royalty-Bearing Product-by-Royalty-Bearing Product basis as follows:: Portion of Annual Net Sales [ **** ] [ **** ] Portion of Annual Net Sales [ **** ] [ **** ]
Appears in 1 contract
Sources: Assignment and License Agreement (Avant Immunotherapeutics Inc)